To evaluate the efficacy and safety of oral interventions in adults with both Fibromyalgia syndrome (FMS) and Irritable bowel syndrome (IBS), focusing on pain reduction and secondary outcomes.
Key Findings:
Current treatment strategies include pharmacological agents like pregabalin and cyclobenzaprine, with varying degrees of efficacy.
Dietary modifications and probiotics have shown inconsistent results in symptom management, with some studies reporting significant improvements.
A personalized medicine approach may yield better outcomes due to heterogeneity in treatment responses.
Interpretation:
The review highlights the complexity of treating FMS and IBS comorbidity, emphasizing the need for tailored interventions that consider individual symptom profiles and underlying mechanisms.
Limitations:
Limited number of studies included in the review.
Inconsistencies in findings regarding the efficacy of probiotics and dietary interventions.
Potential biases in the included studies affecting the overall conclusions, including publication bias.
Conclusion:
A multidimensional therapeutic approach is essential for managing FMS and IBS comorbidity, with further research needed to establish effective treatment protocols.
